OSLO,
Norway, Oct. 20, 2022 /PRNewswire/ -- Navamedic
ASA (OSE: NAVA) today announces the launch of
ForlaxGO® across pharmacies in
Norway, Sweden, Finland and Denmark.
ForlaxGO® is a unique product that
relieves the symptoms of occasional constipation in adults and
children above 8 years of age. The launch is part of a
long-term agreement with Ipsen Consumer HealthCare, a reputable
French pharmaceutical company, whereby Navamedic is the exclusive
partner in the Nordics.
"Following the long-term agreement with Ipsen and the subsequent
launch of SmectaGO® in February, we are pleased to
announce the launch of ForlaxGO®, the second product
launch stemming from this agreement. With only 20 percent of those
suffering from constipation and other gastro conditions seeking
treatment, we believe we can improve people's lives by making
products such as ForlaxGO® accessible and increasing
awareness of treatment options. ForlaxGO® is
already well established on the European continent, and we are
confident that our local insight and market access will drive the
development of this treatment category in the Nordics," says
Kathrine Gamborg Andreassen, CEO of
Navamedic ASA.
ForlaxGO® is an on-the-go, ready-to-drink
suspension that relieves the symptoms of occasional
constipation in adults and children above 8 years of age. The main
component of the product is macrogol, which provides a sense of
natural relief. ForlaxGO® is presented as a
ready-to-use solution in a single-dose sachet and can be bought at
pharmacies without a prescription.
Constipation is defined as slow, hard or infrequent stools. The
problem is widespread among older people and is three times as
common among women as men. 20 percent of the population experience
or live with constipation, and about 10 percent use laxatives.
"We continue to accelerate growth by launching new products such
as ForlaxGO®, underpinning our target of 20 percent
annual organic growth and the mid-term ambition of building a
NOK 1 billion company," says
Kathrine Gamborg Andreassen, CEO of
Navamedic ASA.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO,
Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
Navamedic ASA is a Nordic pharma company and reliable
provider of high-quality products, delivered to hospitals and
through pharmacies, meeting the specific needs of patients and
consumers by leveraging its highly scalable market access platform,
leading category competence and local knowledge. Navamedic is
present in all the Nordic countries, the Baltics and Benelux, with
sales representation in the UK and Greece. Navamedic is headquartered in
Oslo, Norway, and listed on the
Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com
This information is subject to the disclosure requirements
pursuant to section 5 -12 of the Norwegian Securities Trading
Act.
View original
content:https://www.prnewswire.co.uk/news-releases/navamedic-asa-launches-forlaxgo---an-innovative-on-the-go-product-for-the-treatment-of-constipation-301654537.html
